Nastech Licenses RNAi IP From City of Hope to Develop siRNA Drugs | GenomeWeb
NEW YORK (GenomeWeb News) — Nastech Pharmaceutical has licensed RNAi intellectual property and technology from the City of Hope, the company said today.
Nastech licensed City of Hope’s Dicer-Substrate RNA patents and technology in order to develop short-interfering RNA-based drugs for diseases related to protein over-production.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.